These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9749442)

  • 1. Issues for statisticians in pharmaco-economic evaluations.
    Grieve AP
    Stat Med; 1998 Aug 15-30; 17(15-16):1715-23; discussion 1741-3. PubMed ID: 9749442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical issues in equivalence trials.
    Ebbutt AF; Frith L
    Stat Med; 1998 Aug 15-30; 17(15-16):1691-701. PubMed ID: 9749440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes.
    Drummond M; O'Brien B
    Health Econ; 1993 Oct; 2(3):205-12. PubMed ID: 8275165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying Bayesian ideas in drug development and clinical trials.
    Spiegelhalter DJ; Freedman LS; Parmar MK
    Stat Med; 1993 Aug; 12(15-16):1501-11; discussion 1513-7. PubMed ID: 8248659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rank-order stability analysis (ROSA): testing pharmacoeconomic data.
    Einarson TR; Arikian SR; Doyle JJ
    Med Decis Making; 1995; 15(4):367-72. PubMed ID: 8544680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
    Andersson F
    Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological approaches to pharmaco-economics.
    Souêtre EJ; Qing W; Hardens M
    Fundam Clin Pharmacol; 1994; 8(2):101-7. PubMed ID: 8020868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
    Briggs AH; O'Brien BJ; Blackhouse G
    Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.